Decker Retirement Planning Inc. Invests $26,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Decker Retirement Planning Inc. bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the 4th quarter, Holdings Channel reports. The firm bought 3,864 shares of the company’s stock, valued at approximately $26,000.

A number of other institutional investors have also added to or reduced their stakes in RXRX. Axxcess Wealth Management LLC grew its position in shares of Recursion Pharmaceuticals by 4.3% in the 3rd quarter. Axxcess Wealth Management LLC now owns 43,884 shares of the company’s stock valued at $289,000 after acquiring an additional 1,795 shares during the period. Green Alpha Advisors LLC lifted its stake in Recursion Pharmaceuticals by 2.9% in the 3rd quarter. Green Alpha Advisors LLC now owns 64,799 shares of the company’s stock valued at $427,000 after purchasing an additional 1,800 shares during the last quarter. Wedmont Private Capital grew its holdings in Recursion Pharmaceuticals by 10.6% during the fourth quarter. Wedmont Private Capital now owns 20,943 shares of the company’s stock worth $144,000 after purchasing an additional 2,000 shares during the period. Amalgamated Bank increased its position in Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares during the last quarter. Finally, Victory Capital Management Inc. raised its stake in Recursion Pharmaceuticals by 13.5% in the second quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after buying an additional 2,598 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the completion of the transaction, the director now directly owns 7,066,113 shares of the company’s stock, valued at $53,985,103.32. The trade was a 0.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,894 shares of company stock valued at $317,139 in the last quarter. Company insiders own 15.75% of the company’s stock.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $6.53 on Friday. The firm has a market cap of $2.55 billion, a P/E ratio of -4.27 and a beta of 0.85. The business’s 50 day moving average is $6.90 and its 200-day moving average is $6.95. The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. Recursion Pharmaceuticals, Inc. has a 1-year low of $5.60 and a 1-year high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same period in the prior year, the business posted ($0.43) EPS. The firm’s quarterly revenue was up 147.6% compared to the same quarter last year. Equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. KeyCorp decreased their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $8.75.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.